iBio, Inc. (IBIO)
1.11
-0.02
(-1.33%)
USD |
NASDAQ |
Oct 05, 15:59
iBio EPS Diluted (Quarterly) : -0.1903 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1903 |
| March 31, 2026 | -0.0646 |
| December 31, 2025 | -0.0907 |
| September 30, 2025 | -0.108 |
| June 30, 2025 | -0.3144 |
| March 31, 2025 | -0.4929 |
| December 31, 2024 | -0.4779 |
| September 30, 2024 | -0.4621 |
| June 30, 2024 | -0.9019 |
| March 31, 2024 | -0.8543 |
| December 31, 2023 | -4.424 |
| September 30, 2023 | -4.795 |
| June 30, 2023 | -5.941 |
| March 31, 2023 | -11.06 |
| December 31, 2022 | -68.43 |
| September 30, 2022 | -41.01 |
| June 30, 2022 | -977.06 |
| March 31, 2022 | -28.42 |
| December 31, 2021 | -27.39 |
| September 30, 2021 | -20.66 |
| June 30, 2021 | 0.115 |
| March 31, 2021 | -17.92 |
| December 31, 2020 | -21.78 |
| September 30, 2020 | -23.39 |
| June 30, 2020 | -12.86 |
| Date | Value |
|---|---|
| March 31, 2020 | -29.66 |
| December 31, 2019 | -343.84 |
| September 30, 2019 | -103.30 |
| June 30, 2019 | -114.47 |
| March 31, 2019 | -111.50 |
| December 31, 2018 | -121.31 |
| September 30, 2018 | -124.74 |
| June 30, 2018 | -170.00 |
| March 31, 2018 | -150.00 |
| December 31, 2017 | -200.00 |
| September 30, 2017 | -200.00 |
| June 30, 2017 | -250.00 |
| March 31, 2017 | -200.00 |
| December 31, 2016 | -200.00 |
| September 30, 2016 | -150.00 |
| June 30, 2016 | -150.00 |
| March 31, 2016 | -200.00 |
| December 31, 2015 | -150.00 |
| September 30, 2015 | -100.00 |
| June 30, 2015 | -100.00 |
| March 31, 2015 | -100.00 |
| December 31, 2014 | -100.00 |
| September 30, 2014 | -100.00 |
| June 30, 2014 | -87.00 |
| March 31, 2014 | -100.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
| Biogen, Inc. | 0.6557 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -10.60M |
| Total Expenses (Quarterly) | 10.60M |
| Enterprise Value | -23.18M |
| Earnings Yield | -40.86% |
| Normalized Earnings Yield | -37.95 |